Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens — Stella

Recruiting

Back to HER2-positive Gastric Cancer trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Key details

Phase

Early testing / Safety & dosing

Sponsor

Zhejiang Cancer Hospital

Enrollment target

~35 participants

Started

September 2024

Primary completion

August 2026

Age range

18 Years – 75 Years

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov